Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Recent pharmacological progress ofGinkgo biloba extract for cardiovascular and neuronal diseases

  • 35 Accesses

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Itil T, Martorano D. Natural substances in psychiatry (Ginkgo biloba in Dementia). Psychopharmacol Bulletin 1995; 31:147.

  2. 2.

    Kleijnen J, Knipsichild P.Ginkgo biloba. Lancet 1992; 340:1136.

  3. 3.

    1994; 9:10.

  4. 4.

    Braquet P, Hosford D. Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents. J Ethnopharmacol 1991; 32:135.

  5. 5.

    Auguest M, Delaflotte S, Hellegouarch A, et al. The pharmacological basis for the vascular impact ofGinkgo biloba extract. In: Funfgeld EW(ed), Rokan (Ginkgo Biloba). Recent results in pharmacology and clinic. Berlin, Heidelberg, New York: Springer-Verlag, 1988:169–179

  6. 6.

    Chen FY, Lee T J-F. Role of nitric oxide in neurogenic vasodilation of porcine cerebral artery. J Pharmacol Exper Ther 1993; 265:339–345

  7. 7.

    Marcocci L, Maguire JJ, Droy-Lefaix MT et al. The nitric oxide -scavenging properties ofGinkgo biloba extract EGb 761. Biochem Biophy Res Commun 1994; 201:748.

  8. 8.

    1995;15(5):320.

  9. 9.

    Spinnewyn B, et al. Effects ofGinkgo biloba on a cerebral ischemia model in gerbils. In: Funfgeld EW(ed), Rokan (Ginkgo Biloba). Recent results in pharmacology and clinic. Berlin, Heidelberg, New York: Springer-Verlag, 1988: 143–152

  10. 10.

    Smith PF, Maclennan K, Darington CL. The neuroprotective properties of theGinkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). J Ethnopharmacol 1996;50:131.

  11. 11.

    Etienne A, Hecquet F, Clostre F. Mechanisms of effect ofGinkgo biloba extract on experimental cerebraledema. In: Funfgeld EW(ed), Rokan (Ginkgo Biloba). Recent results in pharmacology and clinic. Berlin, Heidelberg, New York: Springer-Verlag, 1988:133–142.

  12. 12.

    Tighilet B, Lacour M. Pharmacological activity of theGinkgo biloba extract (EGb 761) on equilibrium function recovery in the unilateral neurectomized cat. J Vestibular Res 1995;5:187.

  13. 13.

    Maclennenan K, Smith PF, Darlington CL. Ginkgolides B accelerates vestibular compensation of spontaneous ocular nystagmus in guinea-pig following unilateral labyrinthectomy. Exper Neurol 1995; 131:273.

  14. 14.

    Oyama Y, Fuchs PA, Katayama N, et al. Myricetin and quercetin, the flavonoid constitutes ofGinkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca2+ -loaded brain neurons. Brain Res 1994;635:125.

  15. 15.

    Guillon JM, Rochette L, Baranes J. Effects ofGinkgo biloba extract on two models of experimental myocardial ischemia. In: Funfgeld EW (ed), Rokan (Ginkgo Biloba). Recent results in pharmacology and clinic. Berlin, Heidelberg, New York: Springer-Verlag, 1988:153–161.

  16. 16.

    Haramaki N, et al. Effects of natural antioxidantGinkgo biloba extract (EGB 761) on myocardial ischemia/reperfusion injury. Free Radical Biol Med 1994; 16:789.

  17. 17.

    Tosaki Al.Ginkgo biloba extract (EGb 761) improves postischemic function in isolated preconditioned working rat hearts. Coronary Artery Dis 1994; 5:443.

  18. 18.

    Robak J, Gryglewski RJ. Flavonoids are scavengers of superoxide anions. Biochem Pharmacol 1988;37:837.

  19. 19.

    Ratty AK, et al. Interaction of flavonoids with 1, lDiphenyl-2-picryl hydrazyl free radical, liposomal membrane and soy bean lipoxygenase-I. Biochem Pharmacol 1988; 37:989–995.

  20. 20.

    Pincemail J, Deby C. The antiradical properties ofGinkgo biloba extract. In: Funfgeld EW(ed), Rökan (Ginkgo Biloba). Recent results in pharmacology and clinic. Berlin, Heidelberg, New York: Springer-Verlag, 1988:71–82.

  21. 21.

    Maitra I, et al. Peroxyl radical scavenging activity ofGinkgo biloba extract EGb 761. Biochem Pharmacol 1995; 49:1649.

  22. 22.

    Bolli R. Oxygen derived free radicals and myocardial reperfusion injury: an overview. Cardiovasc Drugs Ther 1991; 5:249–268.

  23. 23.

    Chen X, Liu LY, Cai CQ. Ramprilat preconditions the DPPH free radical-damaged aortic endothelium. J Mol Cell Cardio 1995; 27(6):A156.

  24. 24.

    Yan LJ, Droy-Lefaix MT, Packer L.Ginkgo biloba extract (EGB 761) protects human low density lipoproteins against oxidative modification mediated by copper. Biochem Biophy Res Commun 1995;212:360.

  25. 25.

    Dumont E, D’Arbigny P, Nouvelot A. Protection of polysaturated fatty acids against iron-dependent lipid peroxidation by aGinkgo biloba extract (EGB 761). Methods and Findings in Exp and Clin Pharmacol 1995;17:83.

  26. 26.

    Shen J-G, Zhou DY. Efficiency ofGinkgo biloba extract (EGB 761) in antioxidant protection against myocardial is chemia and reperfusion injury. Biochem and Mol Biol International. 1995;35:125.

  27. 27.

    Allard M. Treatment of old age disorders withGinkgo biloba extract. From Pharmacology to clinic. In: Funfgeld EW(ed), Rokan (Ginkgo Biloba). Recent results in pharmacology and clinic. Berlin, Heidelberg, New York: Springer-Verlag, 1988:201–211.

  28. 28.

    Petkov VD, et al. Memory effects of standardized extracts ofPanax ginseng (G115),Ginkgo biloba (GK 501) and their combination Gincosan (PHL-00701). Planta Medica 1993; 59:106.

Download references

Author information

Correspondence to Xiu Chen or Wei-Zhou Chen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chen, X., Chen, W. Recent pharmacological progress ofGinkgo biloba extract for cardiovascular and neuronal diseases. CJIM 2, 300–304 (1996). https://doi.org/10.1007/BF02934707

Download citation

Keywords

  • DPPH
  • Platelet Activate Factor
  • Myricetin
  • Intermittent Claudication
  • Ginkgo Biloba Extract